<TEXT>&#2;<DATELINE>2005-07-12</DATELINE><TITLE>SARS Vaccine Development</TITLE><BODY>Developing effective and safe vaccines is urgently needed to prevent infection by severe acute respiratory syndrome (SARS)â€“associated coronavirus (SARS-CoV). The inactivated SARS-CoV vaccine may be the first one available for clinical use because it is easy to generate; however, safety is the main concern. The spike (S) protein of SARS-CoV is the major inducer of neutralizing antibodies, and the receptor-binding domain (RBD) in the S1 subunit of S protein contains multiple conformational neutralizing epitopes. This suggests that recombinant proteins containing RBD and vectors encoding the RBD sequence can be used to develop safe and effective SARS vaccines.&#3;</BODY></TEXT>